Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.
Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. Kadia TM, et al. Among authors: jain p. Cancer. 2016 Nov 15;122(22):3484-3491. doi: 10.1002/cncr.30203. Epub 2016 Jul 26. Cancer. 2016. PMID: 27463065 Free PMC article.
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. Takahashi K, et al. Among authors: jain p. Cancer. 2016 Nov 15;122(21):3336-3343. doi: 10.1002/cncr.30197. Epub 2016 Aug 10. Cancer. 2016. PMID: 27509035 Free PMC article. Clinical Trial.
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. Kanagal-Shamanna R, et al. Among authors: jain n, jain p. Cancer. 2017 Oct 1;123(19):3717-3724. doi: 10.1002/cncr.30810. Epub 2017 Jun 13. Cancer. 2017. PMID: 28608976 Free PMC article.
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Jain P, et al. Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25. Cancer. 2017. PMID: 28743165 Free PMC article.
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Jain P, et al. Br J Haematol. 2018 Sep;182(5):718-723. doi: 10.1111/bjh.14857. Epub 2017 Aug 2. Br J Haematol. 2018. PMID: 28771675 Free PMC article. No abstract available.
3,214 results